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Abstract 
Purpose: To formulate and determine the release profile of zidovudine (AZT)-loaded solidified lipid 
microparticles (SLMs). 
Methods: Different concentrations (0, 1, 2, 3 and 5 %w/w) of zidovudine (AZT) were formulated into 
microparticles in melt dispersion of Phospholipon® 90H and goat fat in the ratio 1:1, 2:1, 2:3 and 1:3 
followed by lyophilization. They were characterized for particle size, yield, entrapment efficiency (EE) 
and loading capacity (LC). In vitro release kinetics and mechanism of release were assessed 
sequentially in simulated gastric fluid (SGF, pH 1.2)and simulated intestinal fluid (SIF, pH 7.2).  
Results: The ratio 1: 1 formulation was the most stable in terms of physical observation.. Particle size 
analysis indicated that the particles were irregular in shape with size ranging from 5.10 ± 0.10 to 13.40 ± 
2.20 µm. Yield decreased with increase in drug concentrations in the SLMs formulations. EE data 
showed that the microparticles containing 1 % w/w of AZT had the highest entrapment efficiency of 74.0 
± 0.03 %. LC also decreased with increase in concentration of AZT. AZT tablet released most of its 
content within 5 min with a sharp decrease in the concentration but the SLMs maintained its release for 
8 to 12 h in different batches 
Conclusion: The results show that drug content has influence on drug release from the SLMs, but not 
on the mechanism of release. Furthermore, dose dumping was avoided and drug release mechanism 
was mostly non-Fickian while for the reference (commercial) tablet, it was Fickian. 
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Zidovudine (AZT) is the first anti-retroviral 
compound approved for clinical use but the main 
limitation to its therapeutic effectiveness is its 
dose-dependent hematological toxicity, low 
therapeutic index, short biological half-life, and 
poor bioavailability [1, 2]. There is growing 
interest in lipid-based systems in drug discovery 
and product development to effectively overcome 
physical and biological barriers related to poor 
aqueous solubility and stability, membrane 
permeability, drug efflux and availability [3, 4]. 
The rapid growth in the use of lipid-based drug 
delivery systems is primarily due to the diversity 
and versatility of pharmaceutical grade lipid 
excipients and drug formulations and their 
compatibility with liquid, semi-solid and solid 
dosage forms [5, 6].   
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Solid lipid microparticles (SLMs) were developed 
recently and have so far been considered a 
promising drug carrier system, especially with a 
view to giving the incorporated active substance 
a sustained-release profile [7]. Compared with 
other carriers such as liposomes and 
microparticles, SLMs combine several of those 
carriers’ advantages (possibility of controlled 
drug release and drug targeting), while avoiding 
some of their disadvantages such as the use of 
organic solvent, biotoxicity of the carrier system, 
chemical and physical storage instability for both 
the carrier and the drug, high cost of ingredients, 
difficulty in preparation and low scale-up potential 
[8-11]. Uronnachi et al developed and 
characterized AZT-based SLM for control 
delivery [12] and demonstrated their safety and 
efficacy of lipid-based carriers that make them 
potential alternative drug carrier materials to 
polymers. The most important limitation of SLMs 
is that drugs to be incorporated into SLMs must 
be lipophilic enough to ensure high entrapment 
efficiency [13]. 
 
Thus the aim of study was to formulate and 
determine the kinetics and mechanism of release 
profile of AZT-loaded in the formulated SLMs and 






The materials used were Phospholipon® 90H, a 
hydrogenated lecithin (Phospholipid GmbH, Köln, 
Germany), thiomersal, Poloxamer 188 (a non-
ionic tri-block copolymers composed of a central 
hydrophobic chain of polyoxypropylene flanked 
by two hydrophilic chains of polyoxythylene 
(BASF, Germany), zidovudine (a gift from Fidson 
Healthcare, Nigeria), hydrochloric acid, sodium 
chloride, sodium hydroxide, monobasic sodium 
phosphate (Merck, Darmstadt, Germany),  
cyclophosphamide (Oncomide®, Khandelwal, 
India) and distilled water (Lion Water, University 
of Nigeria, Nsukka, Nigeria). All other reagents 
and solvents were of analytical grade and used 
as supplied.  
 
Extraction of goat fat 
 
This was carried out according to the procedure 
outlined by Attama and Nkemnele [6]. Briefly, the 
adipose tissue of Capra hircus was grated and 
subjected to moist heat by boiling with about half 
its weight of water in a water bath for 45 min. The 
molten fat was filtered through a muslin cloth and 
later separated from the aqueous phase after 
cooling. The extracted fat was further subjected 
to purification by passing it through a column of 
activated charcoal and bentonite (2:1) at 100 oC 
at a ratio of 10 g of the fat to 1 g of the column 
material. The fat was stored in a refrigerator until 
used. 
 
Formulation of SLMs 
 
The reverse micellar microparticles (solid lipid 
microparticles) were prepared to contain: lipid 
matrix (7.5 %w/w), zidovudine (0, 1, 2, 3, 5 
%w/w), Poloxamer 188 (1 %w/w), thiomersal 
(0.001 %w/w), sorbitol (4 %w/w) and water (to 
100 %w/w). The lipid matrix consisted of goat fat 
and Phospholipon® 90H (1:1, 2:1, 3:1 and 2:3). 
For each batch, the lipid matrix was placed in a 
stainless steel bowl and heated at 70 oC until it 
had completely melted. The drug was poured 
into the melted matrix and mixed. The remaining 
excipients were weighed out appropriately and 
mixed with the corresponding quantity of water. 
The excipients mixture with water at 70 ᵒC was 
poured into the lipid matrix-drug mixture and 
homogenized at 5000 rpm for 10 min with Ultra-
turrax homogenizer (IKA® 25, Bonn-Bad 
Godesberg, Germany), a creamy emulsion was 
formed. The hot emulsion was then poured into 
bottle and allowed to recrystallize at room 
temperature for 24 h. The same procedure was 
repeated for the various lipid matrices.  
The dispersions were left on the shelf at room 
temperature for one week to determine their 
short-term stability. At the end of the week, it was 
observed that only the 1:1 ratio was stable while 
the other ratios were unstable, thus they were 
discarded. The stable dispersion was then 
lyophilized to get the microparticles. 
 
Evaluation of yield of SLM 
 
The yield was determined by relating the weight 
of the SLMs (W1) obtained to the total weight of 
the ingredients (W2) used in producing the SLMs, 
as in Eq 1. 
 
Yield (%) = (W1/W0)100 …………………… (1) 
 
Particle size and morphology 
 
The morphology and particle size analysis of the 
freeze dried samples were carried out 48 h after 
production. Approximately 5 mg of the samples 
from each batch was dispersed in distilled water 
and smeared on a microscopic slide using a 
glass rod. The mixture was covered with a cover 
slip and viewed with a photomicroscope (Hund®, 
Weltzlar, Germany) attached with a digital 
camera at a magnification of 1000. Triplicate 
readings were taken. 
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Determination of encapsulation efficiency 
(EE) 
 
The entrapment efficiency was determined by 
solvent extraction followed by quantification. A 
sample (0.5 g) of the SLMs was mixed with 50 ml 
of ethanol. Resulting mixture was allowed to 
stand for 12 h and then filtered through a filter 
paper (Whatman no.1). The filtrate was then 
diluted 10-fold with ethanol and the resulting 
solution was analyzed spectrophotometrically 
(UNICO-3102, England). Determination was 
done in triplicates. Amount of drug encapsulated 
in the microparticles was calculated with 
reference to a standard Beer’s plot for zidovudine 
to obtain EE as the ratio of actual drug content to 
theoretical drug content, expressed as 
percentage [14]. 
 
Assessment of loading capacity 
 
Loading capacity (LC) was assessed as the ratio 
of the entrapped zidovudine to the total weight of 
the lipids [15], expressed as a percentage.  
 
In vitro release studies  
 
A sample of SLM was placed in a dialysis 
membrane (MWCO 6000-8000 Spectrum Labs, 
The Netherland) tied at both ends and 
suspended in 250 ml of SGF in a dissolution 
apparatus set to rotate at 100 rpm. The 
temperature was set at 37 oC. At intervals of 5, 
10, 20 and 30, 60 and 120 min, respectively, 5 ml 
aliquots of the dissolution medium was collected 
and immediately replaced with 5 ml of fresh SGF. 
The medium was changed to SIF after 2 h, and 
at hourly intervals, 5 ml aliquots of the dissolution 
medium was collected and immediately replaced 
with 5 ml of fresh SIF. The drug release in this 
medium was then assessed for another 10 h. 
The withdrawn samples were analyzed 
spectrophotometrically (UNICO-3102, England) 
at a wavelength of 290 nm. 
 
Analysis of kinetics of drug release 
 
The dissolution data for the SLMs were also 
analyzed to determine the in vitro release 
kinetics. Four kinetic models viz: zero-order, first 
order, Higuchi [16] and Korsmeyer-Peppas [17], 
as in Eqs 2 – 5, respectively were applied. 
 
Qt  =  Kot ………………………..…….…. (2) 
InQt = InQo-K1t ……………………….…. (3) 
Qt   = Kh.S t …….……………………. (4) 
Mt/̸ ∞ =Ktn ………….…………………... (5) 
 
where Q is the amount of drug released in time t, 
Qo is the initial amount of drug in the 
microparticles, Ko, K1, and KH are the rate 
constants of Zero order, First order and Higuchi 
rate equations, respectively. For the Peppas and 
Korsmeyer model, Mt is the amount of drug 
released at time t.  M  is the amount of drug 
released at time =	∞, n is the diffusional 
exponent indicative of the mechanism of drug 
release, K is the power law constant, Mt/M  is 
the fraction of the drug released. If n	≤ 0.43, 
Fickian diffusion (case I) applies, 0.43  n  
0.89 is non-Fickian transport and n  0.89 is 





All experiments were performed at least in 
triplicate and the results expressed as mean  
SD. ANOVA and students t-tests were performed 
on the data, as appropriate, using Microsoft 
Excel version 2007. Differences were considered 




Characteristics of SLMs 
 
The production yield, particle size, loading 
capacity and entrapment efficiency of the SLMs 
are shown in Table 1. Batch B1, containing 1 % 
AZT showed the highest yield. 
 
In vitro release  
 
The in vitro release profile of different 
formulations and the pure sample is shown in 
Table. 1.    
 
Table 1: Some characteristics of the SLMs (± SD, n = 3)   
 
Batch code                     Yield (%)                Mean particle size (μm)        LC (%)               EE (%) 
B1   86.3 ± 4.70                  5.10 ± 0.10                       90.80  ± 0.20                                       74.00 ± 0.03 
B2    85.4 ± 2.60                   7.40 ± 0.70                      88.17  ± 0.60                                                        55.88 ± 0.01 
B3 78.5 ± 1.50                   9.73 ± 0.50                      82.19  ± 0.35                                                        34.60 ± 0.01 
B4 78.2 ± 2.20                 13.40 ± 2.20                     74.23  ± 0.40                           20.16 ± 0.05 
B5 75.4 ± 1.20               3.30 ± 0.00                       - - 
 B1 to B5 denote 1, 2, 3, 5 and 0 % AZT, respectively, LC = loading capacity;  EE = entrapment efficiency 
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Table 1: Quantity of drug release in SGF and SIF after 12 h 
 









0.08 3.57 7.14 10.71 20.94 146.67 
0.17 5.24 8.81 14.35 17.14 13.09 
0.33 5.24 10.47 15.6 17.14 14.29 
0.5 5.24 8.57 15.6 17.85 8.81 
1 5.47 9.28 17.88 14.04 11.19 
2 6.9 10.47 19.14 17.37 10.71 
3 8.112 11.23 6.66 13.94 11.67 
4 9.152 12.48 5.82 16.22 13.37 
5 8.32 11.86 4.99 14.98 16.05 
6 9.152 12.48 4.58 15.81 15.84 
7 7.904 23.3 5.41 15.6 17.7 
8 13.31 32.03 5.62 14.77 17.08 
9 13.52 13.94 4.99 19.34 17.08 
10 14.35 12.89 6.45 17.68 17.9 
1 14.35 13.73 6.24 17.68 19.55 
12 15.6 14.77 5.82 11.02 9.88 
 
 Table 2: Release kinetic parameters for the formulations 
 
Batches   Zero order First order Higuchi Korsmeyer 
 r² K0 r² K1 r² Kh r² n 
B1 in SGF        0.8970 0.054 0.8370 0.007 0.9910 1.166 0.9970 0.538 
B1 in SIF         0.8930 0.024 0.9390 0.002 0.9860 1.173 0.9870 0.520 
B2 in SGF       0.8340 0.087 0.7860 0.008 0.9660 1.311 0.9590 0.580 
B2 in SIF         0.9420 0.025 0.9330 0.002 0.9800 0.599 0.9800 0.466 
B3 in SGF       0.7990 0.159 0.7850 0.020 0.9700 0.361 0.9530 0.865 
B3 in SIF        0.8740 0.012 0.8710 0.001 0.9310 0.381 0.9820 0.351 
B4 in SGF       0.8870 0.144 0.8050 0.010 0.9800 5.971 0.9060 0.882 
B4 in SIF        0.9200 0.035 0.8330 0.002 0.9220 1.374 0.9490 0.559 
AZT in 
SGF     
0.9000 0.186 0.7350 0.008 0.9920 0.485 0.9700 0.285 
AZT in 
SIF     
0.8730 0.034 0.8230 0.002 0.9580 0.283 0.9800 0.288 
Key: r2 = correlation coefficient, K0 = zero order rate constant, K1 = first order rate constant, Kh = Higuchi rate constant, n = 
Korsmeyer constant  
 
Release kinetics  
 
Drug release from monolithic spheres has been 
reported variously as taking place by numerous 
differing mechanisms, which include surface 
erosion, total sphere disintegration, microsphere 
hydration (or swelling), drug diffusion and 




The LC and EE of the AZT in the SLMs showed 
a decrease in the quantity of AZT entrapped with 
increasing drug concentrations as shown in 
Table 1. The matrix incorporating 1 % AZT (B1) 
had the highest percentage entrapped while the 
formulation containing 5 % AZT (B4) had the 
least entrapment efficiency. This could be as a 
result of saturation of the lipid matrix [18] as 
adequate drug loading is the prerequisite to 
obtaining a high solubility of the drug in the lipid 
melt. Generally, solubility decreased after cooling 
down the lipid melt and might even be lower in 
the solid lipid. The presence of mono and 
diglycerides in the lipid used as matrix material 
promotes drug solubilisation [19]. The chemical 
nature of the lipid is also important because lipids 
that form highly crystalline particles with a perfect 
lattice (such as monoacid triglycerides) lead to 
drug expulsion [20].    
 
The particle size analysis of the microspheres 
revealed a variation in the sizes of the different 
formulations with the 1 % AZT (B1) having the 
least average   particle   size while the 5 % AZT 
(B4) had the greatest average particle size. 
Differences in sizes of individual particles may be 
adduced to the surface of viewing which could 
have been ‘edge-on’ or ‘side on’. The particle 
sizes of the AZT-loaded SLMs were significantly 
higher than the particle size of the unloaded 
batch (B5).  
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In vitro drug dissolution studies Fig. 1 showed 
that the 1 % AZT (B1) gave a gradual release of 
AZT. The 3 % AZT (B3) and 5 % AZT (B4) 
formulations had an initial high release which 
could be adduced to the presence of zidovudine 
on the surface of the microparticles as a result of 
saturation of the lipid matrix. According to Reddy 
et al [21] this initial in vitro burst release could be 
as a result of adsorption on the surface of the 
microparticle, or precipitation from the superficial 
lipid matrix. This could be advantageous in a 
formulation since it provides a quantity of drug to 
the body within a short time for therapeutic 
activity to commence before subsequent 
quantities are delivered gradually to maintain this 
activity. In contrast, the commercial AZT tablet, 
released almost all of its drug content within 5 
min. According to Galinski and Svenson [22], 
prolonged release dosage forms have the 
additional advantage of giving a lesser fluctuation 
in blood levels of the drug than with rapidly 
absorbed dosage forms. Also, the study of White 
[23] revealed that the reduction in the rapidity of 
change of blood concentrations of some drugs 
could lead to an improvement in the efficacy, and 
a decrease in adverse effects of these drugs. 
There is significant difference in the release of 
the AZT from the SLMs (B1-B4) and the 
commercial tablet (B5) within the first 5 min of 
administration. This explained that those 
dumping is experienced in the commercial 
sample but not on the SLMs-loaded with AZT 
 
Determining the correlation coefficient assessed 
the fitness of the data into various kinetic models. 
The rate constants for the respective models 
were calculated from their slopes [24] The results 
obtained as shown in Table 2 revealed that the 
best fit release kinetics was obtained with the 
Korsmeyer’s plot while the Higuchi plot also 
showed a high correlation for the data. Thus drug 
release from the matrix of the solid lipid 
microparticles could be described as non- 
Fickian for the 1 %, 2 % and 3 % AZT-loaded 
solidified lipid microparticles, with a value of   
0.43 < n < 0.85, while drug release from the 
zidovudine tablets was Fickian with an n-value < 
0.43. This thus means that the drugs are 
released via a diffusion and dissolution 
mechanism. The difference in the release 
mechanisms of the formulated solid lipid 
microparticles and the commercial tablets may 
be due to the tortuosity of the polymer matrix 
which thus restricted the path of diffusion, 
whereas the simple tablet matrix of the 
commercial tablets made diffusion from its matrix 
to be easier and faster. 
 
The difference in the release mechanisms of the 
formulated microparticles and the AZT tablets 
may be due to the tortuosity of the polymer 
matrix which thus restricted the path of diffusion 
whereas the plain tablet matrix of the AZT tablets 
facilitated diffusion from its matrix. This confirms 
that the release of AZT-loaded SLMs followed a 
diffusion controlled mechanism for a non 
sequential analysis while none of the kinetics 
was followed for the sequential release. Since 
the discrete granular particles were non-
disintegrating because of the dominance of lipid 
materials in the formulations, the only logical 
process of drug release would be by diffusion. 
This is accentuated by the fact that the granules 
did not swell, and so drug release would not be 
by gel-erosion.  
 
The presence of surface-active agent in the 
SLMs would be expected to influence the pattern 
of drug release. Clearly, the presence of the 
Phospholipon® 90H caused a shift of drug 
release kinetics from Fickian type exhibited by 
the AZT tablets. This indicates that drug release 
mechanism is independent of drug release 
kinetics [25]. Drug release mechanisms generally 
relate to the interactions between component 
ingredients in a formulation, and this includes the 
possible interactions between active ingredients 




The results indicate that drug concentration has 
influence on the rate of drug release from the 
SLMs, but not on the mechanism of release. 
However, dose dumping was avoided and drug 
release was mostly non-Fickian while that of 




The authors are grateful to Fidson Healthcare, 
Nigeria for the pure sample of zidovudine 
provided and Phospholipon GmbH, Köln, 
Germany for the Phospholipon® 90H used in the 
work.  
 
CONFLICT OF INTEREST 
 
The authors declare no conflict of interest and 
have received no funding for the research or in 




1. Kieburtz KD, Seidllin M, Lambert JS, Dollis R, Reichman 
R, Valentine T.  Extended follow-up of neuropathy 
in patients with AIDS and AIDS related complex 
treated with dideoxyinosine. J Acquir Immuno Defic 
Syndrom. 1992; 5: 60-64. 
Uronnachi et al 
Trop J Pharm Res, February 2014; 13(2): 204  
 
2. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in 
vitro, in vivo evaluation of extended- release matrix 
tablet of zidovudine: Influence of combination of 
hydrophilic and hydrophobic matrix formers. AAPS 
PharmSciTech. 2006; 7(1): Article 1. DOI. 10.1208/ 
pt070101. 
3. Westesen K, Sielkmann B. Solid lipid nanoparticles of 
bioactive agent and method for the manufacture 
and use thereof.  United States Patent. 1998; 
5785-976.  
4. Attama AA, Okafor CE, Builders PF, Okorie O. 
Formulation and in vitro evaluation of a PEGylated 
microscopic lipospheres delivery system for 
cefriaxone sodium. Drug Delivery 2009; 16: 448-
457. 
5. Craig DQM. Lipid matrices for sustained release. An 
academic overview. Bull Tech Gatefosse 2004; 97: 
9-19.   
6. Attama AA, Nkemnele MN. In vitro evaluation of drug 
release from self-emulsifying drug delivery systems 
using a biodegradable homolipid from Capra 
hircus. Int. J. Pharm. 2005; 304: 4-10 
7. Jaspart S, Piel G, Delatte L, Evrad B. Solid lipid 
microparticles: Formulation, preparation, 
characterization, drug release and applications. 
Expert Opin Drug Deliv. 2005; 2: 75–87. 
8. Reithmier H, Hermann J, Gopferich A. Lipid 
microparticles as a parenteral controlled release 
device for peptides. J. Control Rel. 2001; 73: 339–
350. 
9. Milak S, Medicott N, Tucker IG. Solid lipid micro particles 
containing loratadine prepared using a micro mixer. 
J. Microencapsul. 2006; 23: 823–831. 
10. Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, 
Evrad B. Solid lipid microparticles as sustained 
release system for pulmonary drug delivery. Eur. J. 
Pharm. Biopharm. 2007; 65: 47–56. 
11. Umeyor EC, Kenechukwu FC, Ogbonna JD, Chime SA, 
Attama A. Preparation of novel solid lipid 
microparticles loaded with gentamicin and its 
evaluation in vitro and in vivo. J.  Microencap. 
2012; DOI: 10.3109/02652048.2011.651495 
12. Uronnachi EM, Ogbonna JDN, Kenechukwu FC, Attama 
AA, Chime SA. Properties of zidovudine loaded 
solidified reverse micellar microparticles prepared 
by melt dispersion. J Pharmacy Res 2012; 5(5): 
2870-2874. 
13. Long C, Zhang L, Qian Yu. Preparation and crystal 
modification of ibuprofen loaded solid lipid 
microparticles. Chin J Chem. Eng. 2006; 14(4): 
518–525. 
14. Morkhade DM, Joshi SB. Evaluation of gum dammar as a 
novel microencapsulating material for ibuprofen 
and diltiazem hydrochloride. Indian J. Pharm. Sci. 
2007; 67: 263–268. 
15. Doktorovova S, Souto EB. Nanostructured lipid carrier-
based hydrogel formulations for drug delivery: A 
comprehensive review. Expert Opin Drug Deliv. 
2009; 6: 165–176. 
16. Higuchi T. Mechanism of sustained action medication. 
Theoretical analysis of rate of solid drugs dispersed 
in solid matrices. J. Pharm. Sci. 1963; 52: 1145–
1149. 
17. Korsmeyer RW, Peppas NA. Solute and penetrant 
diffusion in swellable polymers ІІІ. Drug release 
from glassy polymers (HEMA-co-NVP) copolymers. 
J. Control Rel. 1983: 1:89-98. 
18. Vivek K, Harivardhan R, Ramachandra SR. Investigation 
of the effect of the lipid matrix on drug entrapment, 
In vitro release, and physical stability of 
olanzapine-loaded solid lipid nanoparticles, AAPS 
PharmSci Tech, 2007;  8(4).  Article 83. 
(http://www.aapspharmscitech.org). 
19. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles 
(SLN) for controlled drug delivery: a review of the 
state of the art. Eur J Pharm Biopharm. 2000; 50:  
161-177.  
20. Westesen K, Bunjes H, Koch MHJ. Physicochemical 
characterization of lipid nanoparticles and 
evaluation of their drug loading capacity and 
sustained release potential. J Control Release. 
1997;48:223–236. doi: 10.1016/S0168-3659(97)00 
046-1. 
21. Reddy HL, Murthy RSR. Etoposide-loaded nanoparticles 
made from glyceride lipids: Formulation, 
characterization, in vitro drug release, and stability 
evaluation. AAPS PharmSciTech. 2005; 6(2): 
E158–E166. doi:  10.1208/pt060224 
22. Galinsky ER, Svenson CK. Basic Pharmacokinetics. In 
Remington: The Science and Practice of 
Pharmacy, 19th edn. Easton P.A, Mack Publishing, 
1995; vol II pp.1127-1144. 
23. White PF. Anesthiology, 1983; 59, 294. 
24. Pachuau L, Sarkar S, Mazumdar B. Formulation and 
evaluation of matrix mic rospheres for 
simultaneous delivery of salbutamol sulphate and 
theophylline. Tropical J. Pharm. Res. 2008; 7(2): 
995-1002. 
25. Okore VC, Ogbonna JDN, Kenechukwu FC. In vitro 
release mechanism of acetylsalicylic acid from 
melt-extrusion granules of dika wax. Abstract, 14th 
Annual Conference of Chemical Society of Nigeria, 
Enugu State Chapter, Nsukka (Nigeria), 2012; p 
15. 
 
